![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARL6IP5 |
Gene summary for ARL6IP5 |
![]() |
Gene information | Species | Human | Gene symbol | ARL6IP5 | Gene ID | 10550 |
Gene name | ADP ribosylation factor like GTPase 6 interacting protein 5 | |
Gene Alias | DERP11 | |
Cytomap | 3p14.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024R371 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10550 | ARL6IP5 | GSM4909285 | Human | Breast | IDC | 8.05e-05 | 3.47e-01 | 0.21 |
10550 | ARL6IP5 | GSM4909286 | Human | Breast | IDC | 8.27e-14 | -3.38e-01 | 0.1081 |
10550 | ARL6IP5 | GSM4909291 | Human | Breast | IDC | 1.36e-05 | -4.21e-01 | 0.1753 |
10550 | ARL6IP5 | GSM4909294 | Human | Breast | IDC | 7.19e-05 | -2.15e-01 | 0.2022 |
10550 | ARL6IP5 | GSM4909296 | Human | Breast | IDC | 7.35e-21 | -4.30e-01 | 0.1524 |
10550 | ARL6IP5 | GSM4909297 | Human | Breast | IDC | 1.84e-23 | -3.04e-01 | 0.1517 |
10550 | ARL6IP5 | GSM4909301 | Human | Breast | IDC | 4.28e-07 | -3.57e-01 | 0.1577 |
10550 | ARL6IP5 | GSM4909309 | Human | Breast | IDC | 3.05e-03 | -2.72e-01 | 0.0483 |
10550 | ARL6IP5 | GSM4909311 | Human | Breast | IDC | 3.91e-46 | -4.77e-01 | 0.1534 |
10550 | ARL6IP5 | GSM4909312 | Human | Breast | IDC | 3.05e-15 | -2.26e-01 | 0.1552 |
10550 | ARL6IP5 | GSM4909313 | Human | Breast | IDC | 6.07e-04 | -9.69e-02 | 0.0391 |
10550 | ARL6IP5 | GSM4909316 | Human | Breast | IDC | 1.50e-02 | -3.89e-01 | 0.21 |
10550 | ARL6IP5 | GSM4909318 | Human | Breast | IDC | 2.87e-07 | -6.06e-01 | 0.2031 |
10550 | ARL6IP5 | GSM4909319 | Human | Breast | IDC | 3.42e-46 | -5.26e-01 | 0.1563 |
10550 | ARL6IP5 | GSM4909320 | Human | Breast | IDC | 2.28e-12 | -4.88e-01 | 0.1575 |
10550 | ARL6IP5 | GSM4909321 | Human | Breast | IDC | 1.27e-27 | -5.22e-01 | 0.1559 |
10550 | ARL6IP5 | brca10 | Human | Breast | Precancer | 1.43e-02 | -3.06e-01 | -0.0029 |
10550 | ARL6IP5 | M2 | Human | Breast | IDC | 1.03e-02 | -4.58e-01 | 0.21 |
10550 | ARL6IP5 | NCCBC11 | Human | Breast | DCIS | 1.87e-04 | -1.11e-01 | 0.1232 |
10550 | ARL6IP5 | NCCBC14 | Human | Breast | DCIS | 1.86e-18 | -5.66e-02 | 0.2021 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:199077823 | Oral cavity | EOLP | protein localization to cell periphery | 65/2218 | 333/18723 | 3.17e-05 | 4.48e-04 | 65 |
GO:006219726 | Oral cavity | EOLP | cellular response to chemical stress | 64/2218 | 337/18723 | 8.49e-05 | 1.01e-03 | 64 |
GO:003109824 | Oral cavity | EOLP | stress-activated protein kinase signaling cascade | 49/2218 | 247/18723 | 1.89e-04 | 1.94e-03 | 49 |
GO:005140324 | Oral cavity | EOLP | stress-activated MAPK cascade | 47/2218 | 239/18723 | 3.11e-04 | 2.91e-03 | 47 |
GO:003459925 | Oral cavity | EOLP | cellular response to oxidative stress | 54/2218 | 288/18723 | 4.04e-04 | 3.58e-03 | 54 |
GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
GO:007030224 | Oral cavity | EOLP | regulation of stress-activated protein kinase signaling cascade | 39/2218 | 195/18723 | 6.89e-04 | 5.70e-03 | 39 |
GO:000863123 | Oral cavity | EOLP | intrinsic apoptotic signaling pathway in response to oxidative stress | 13/2218 | 45/18723 | 1.64e-03 | 1.09e-02 | 13 |
GO:003287224 | Oral cavity | EOLP | regulation of stress-activated MAPK cascade | 37/2218 | 192/18723 | 1.87e-03 | 1.21e-02 | 37 |
GO:005188123 | Oral cavity | EOLP | regulation of mitochondrial membrane potential | 18/2218 | 74/18723 | 2.08e-03 | 1.32e-02 | 18 |
GO:0036473110 | Oral cavity | EOLP | cell death in response to oxidative stress | 20/2218 | 95/18723 | 7.19e-03 | 3.49e-02 | 20 |
GO:003647516 | Oral cavity | EOLP | neuron death in response to oxidative stress | 9/2218 | 31/18723 | 8.00e-03 | 3.78e-02 | 9 |
GO:009719318 | Prostate | BPH | intrinsic apoptotic signaling pathway | 110/3107 | 288/18723 | 7.36e-19 | 2.85e-16 | 110 |
GO:000697918 | Prostate | BPH | response to oxidative stress | 142/3107 | 446/18723 | 8.11e-16 | 1.36e-13 | 142 |
GO:004586218 | Prostate | BPH | positive regulation of proteolysis | 121/3107 | 372/18723 | 2.05e-14 | 2.44e-12 | 121 |
GO:006219718 | Prostate | BPH | cellular response to chemical stress | 110/3107 | 337/18723 | 2.44e-13 | 2.40e-11 | 110 |
GO:005254718 | Prostate | BPH | regulation of peptidase activity | 133/3107 | 461/18723 | 2.08e-11 | 1.43e-09 | 133 |
GO:003459918 | Prostate | BPH | cellular response to oxidative stress | 90/3107 | 288/18723 | 4.70e-10 | 2.43e-08 | 90 |
GO:007265916 | Prostate | BPH | protein localization to plasma membrane | 89/3107 | 284/18723 | 5.00e-10 | 2.56e-08 | 89 |
GO:004328118 | Prostate | BPH | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 71/3107 | 209/18723 | 5.88e-10 | 2.89e-08 | 71 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARL6IP5 | SNV | Missense_Mutation | c.15C>G | p.Ile5Met | p.I5M | O75915 | protein_coding | deleterious(0.05) | benign(0.275) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ARL6IP5 | SNV | Missense_Mutation | novel | c.524G>A | p.Gly175Asp | p.G175D | O75915 | protein_coding | tolerated(0.45) | benign(0.007) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ARL6IP5 | SNV | Missense_Mutation | c.162N>A | p.Met54Ile | p.M54I | O75915 | protein_coding | tolerated(0.67) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ARL6IP5 | SNV | Missense_Mutation | rs757868106 | c.551N>A | p.Ser184Asn | p.S184N | O75915 | protein_coding | tolerated_low_confidence(0.06) | benign(0.003) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
ARL6IP5 | SNV | Missense_Mutation | rs367744231 | c.286N>T | p.Arg96Cys | p.R96C | O75915 | protein_coding | deleterious(0.02) | benign(0.276) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ARL6IP5 | SNV | Missense_Mutation | novel | c.155N>T | p.Ala52Val | p.A52V | O75915 | protein_coding | tolerated(1) | benign(0.014) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARL6IP5 | SNV | Missense_Mutation | rs774792987 | c.287G>A | p.Arg96His | p.R96H | O75915 | protein_coding | tolerated(0.18) | benign(0) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
ARL6IP5 | SNV | Missense_Mutation | c.202N>A | p.Leu68Met | p.L68M | O75915 | protein_coding | tolerated(0.06) | benign(0.037) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ARL6IP5 | SNV | Missense_Mutation | c.447N>T | p.Glu149Asp | p.E149D | O75915 | protein_coding | deleterious(0.03) | possibly_damaging(0.748) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
ARL6IP5 | SNV | Missense_Mutation | rs11542221 | c.413C>T | p.Ser138Leu | p.S138L | O75915 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |